Rosacea

Botulin toxin was first approved by the FDA in 2002 for cosmetic reasons.

Differences in rosacea subtypes were also observed regarding patient sex, continent of origin, and the year of publication.

Dr. Karan Lal provides essential information on rosacea, which the National Rosacea Society estimates to affect 16 million people in the United States.

In data presented at AAD, investigators found increased odds of GERD in patients with rosacea compared to a control group without rosacea.

The investigative team also observed a significant association between psoriasis, IBS, anxiety, and depression in patients with diabetes and rosacea.

Previous research has suggested that current rosacea therapies can also induce burning or stinging sensations in patients.

Among the different rosacea phenotypes included in the study, no statistical difference in ANAs was observed.

Investigators believe that the prevalence of rosacea familiarity had been underestimated in previous reports.

Currently, the use of minocycline is limited orally due to some systemic side effects.

The FDA set a 2020 PDUFA action date for FMX103, a topical foam to treat papulopustular rosacea.

Compared to standard cleansers and moisturizers, natural versions for sensitive skin provided benefits to patients with rosacea who were also taking prescription treatments.

An internist’s perspective on which sessions to attend, from melanoma to inflammatory diseases to cosmetic procedures.

Overall antibiotic prescriptions have dropped, but short-term postoperative prescriptions have increased in recent years.

Rosacea patients are at a higher risk of developing Alzheimer’s disease and dementia, according to new research.

Initial treatment with once-daily ivermectin 1% cream (Soolantra/Galderma) resulted in longer remission for patients suffering from moderate-to-severe papulopustular rosacea, compared to the initial treatment with twice daily metronidazole 0.75% cream.

Rosacea has been linked to a significantly increased risk of developing glioma.

Soolantra (ivermectin) Cream, 1% has been approved for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea.

Early treatment of rosacea is crucial for the prevention of irreversible damage.